# US 2022/0031610 A1 · Pharmaceutical compositions comprising coated api

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031610 A1
- Document ID: US20220031610A1
- Status: Published application
- Kind: A1
- Application number: 17/390,331
- Filed: 2021-07-30
- Published: 2022-02-03
- Earliest claimed: 2020-07-31
- Assignees: Catalent U.K. Swindon Zydis Limited
- Applicants: Catalent U.K. Swindon Zydis Limited
- Inventors: Rosaleen MCLAUGHLIN; Simon Andrew Martyn HOWES; Craig WHEADON; Jonathon WHITEHOUSE; Adam PARKER; Michael John HUTCHINSON
- Web page: https://patentgrep.com/patent/US20220031610A1

## CPC

- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2063: {Proteins, e.g. gelatin}
- A61K 9/2095: {Tabletting processes}
- A61K 9/2813: {Inorganic compounds}
- A61K 9/2826: {Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof}
- A61K 9/2873: {Proteins, e.g. gelatin}
- A61K 9/2893: {Tablet coating processes (mechanical aspects A61J3/06)}
- A61K 9/501: {Inorganic compounds}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising coated API. Excess coating material that is not bound to coated API may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Additionally, the compositions can be formulated to preserve the functional coating of coated API and to minimize aeration of API when mixed into suspension.

## Claims

### Claim 1

A pharmaceutical composition comprising:
85-95% w/w API comprising at least one coating, wherein the at least one coating comprises a water insoluble material and silica;
3-7% w/w matrix former; and
2-6% w/w structure former.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the water insoluble material comprises 10-30% w/w of the API comprising the at least one coating.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the silica comprises 0.5-2% w/w of the API comprising the at least one coating.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the water insoluble material comprises a wax.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the wax comprises carnauba wax.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the silica comprises hydrophobic silica.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the matrix former comprises gelatin.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the structure former comprises mannitol.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, further comprising a viscosity modifier.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the pharmaceutical composition comprises 0.1-1% w/w viscosity modifier.

### Claim 11 (depends on 9)

The pharmaceutical composition of claim 9, wherein the viscosity modifier comprises xanthan gum.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, further comprising a sweetener.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the pharmaceutical composition comprises 0.1-2% w/w sweetener.

### Claim 14 (depends on 12)

The pharmaceutical composition of claim 12, wherein the sweetener is sucralose.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, further comprising a flavoring agent and/or an anti-aeration agent.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein the pharmaceutical composition comprises 0.5-3% w/w flavoring agent and/or anti-aeration agent.

### Claim 17 (depends on 15)

The pharmaceutical composition of claim 15, wherein the flavoring agent and/or anti-aeration agent comprises terpene and/or terpinol.

### Claim 18 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition has a mid volume 60-minute dissolution test result less than or equal to 70% after 15 minutes.

### Claim 19

A method of preparing coated API comprising:
sieving raw API;
mixing sieved raw API and a water insoluble material in a vessel;
applying mechanical energy to the vessel and heating the vessel to a temperature greater than or equal to 50° C.; and
adding silica to the vessel while continuing to apply the mechanical energy and maintaining the temperature of the vessel to form coated API comprising at least one coating comprising water insoluble material and silica.

### Claim 20 (depends on 19)

The method of claim 19, wherein sieving the raw API comprises sieving the raw API to an average particle size of 75-250 microns.

### Claim 21 (depends on 19)

The method of claim 19, further comprising sieving the coated API.

### Claim 22 (depends on 21)

The method of claim 21, wherein sieving the coated API comprises sieving the coated API to an average particle size of 75-250 microns.

### Claim 23 (depends on 19)

The method of claim 19, wherein the ratio of the at least one coating to the API of the API comprising at least one coating is 15-40:60-85.

### Claim 24 (depends on 19)

The method of claim 19, wherein the coated API has a low volume 60 minute dissolution test result less than or equal to 70% after 15 minutes.

### Claim 25

A method of preparing a pharmaceutical composition comprising:
forming a pharmaceutical suspension comprising:
30-50% w/w API comprising at least one coating, wherein the at least one coating comprises a water insoluble material and silica;
1-5% w/w a matrix former;
1-3% w/w a structure former; and
a solvent;
dosing the pharmaceutical suspension into a mold; and
freeze drying the dosed pharmaceutical suspension in the mold to form the pharmaceutical composition.
